{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T18:15:26Z","timestamp":1790100926187,"version":"4.0.1"},"reference-count":49,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","heartfailure.onlinejacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Heart Failure"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1016\/j.jchf.2017.08.023","type":"journal-article","created":{"date-parts":[[2017,11,8]],"date-time":"2017-11-08T17:34:42Z","timestamp":1510162482000},"page":"201-208","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":96,"title":["Anemia in Heart Failure"],"prefix":"10.1016","volume":"6","author":[{"given":"Niels","family":"Grote Beverborg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk J.","family":"van Veldhuisen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"van der Meer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jchf.2017.08.023_bib1","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/nrcardio.2011.77","article-title":"Anemia and iron deficiency in heart failure: mechanisms and therapeutic approaches","volume":"8","author":"van Veldhuisen","year":"2011","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.jchf.2017.08.023_bib2","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1093\/eurheartj\/ehn359","article-title":"Chronic heart failure leads to an expanded plasma volume and pseudoanaemia, but does not lead to a reduction in the body\u2019s red cell volume","volume":"29","author":"Adlbrecht","year":"2008","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jchf.2017.08.023_bib3","doi-asserted-by":"crossref","first-page":"e0125215","DOI":"10.1371\/journal.pone.0125215","article-title":"Erythropoietin in the general population: reference ranges and clinical, biochemical and genetic correlates","volume":"10","author":"Grote Beverborg","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.jchf.2017.08.023_bib4","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/j.jacc.2008.04.061","article-title":"Anemia and mortality in heart failure patients. a systematic review and meta-analysis","volume":"52","author":"Groenveld","year":"2008","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2017.08.023_bib5","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.jacc.2007.07.094","article-title":"Evaluation and long-term prognosis of new-onset, transient, and persistent anemia in ambulatory patients with chronic heart failure","volume":"51","author":"Tang","year":"2008","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2017.08.023_bib6","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.jacc.2011.10.864","article-title":"Baseline anemia is not a predictor of all-cause mortality in outpatients with advanced heart failure or severe renal dysfunction. Results from the Norwegian Heart Failure Registry","volume":"59","author":"Waldum","year":"2012","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2017.08.023_bib7","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.ahj.2013.01.017","article-title":"Iron deficiency in chronic heart failure: an international pooled analysis","volume":"165","author":"Klip","year":"2013","journal-title":"Am Heart J"},{"key":"10.1016\/j.jchf.2017.08.023_bib8","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1016\/j.jacc.2011.04.040","article-title":"Disordered iron homeostasis in chronic heart failure: prevalence, predictors, and relation to anemia, exercise capacity, and survival","volume":"58","author":"Okonko","year":"2011","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2017.08.023_bib9","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1016\/j.jacc.2006.08.034","article-title":"Etiology of anemia in patients with advanced heart failure","volume":"48","author":"Nanas","year":"2006","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2017.08.023_bib10","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1093\/eurheartj\/ehn205","article-title":"Adequacy of endogenous erythropoietin levels and mortality in anaemic heart failure patients","volume":"29","author":"van der Meer","year":"2008","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jchf.2017.08.023_bib11","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1093\/eurheartj\/ehl419","article-title":"Anaemia in chronic heart failure is not only related to impaired renal perfusion and blunted erythropoietin production, but to fluid retention as well","volume":"28","author":"Westenbrink","year":"2007","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jchf.2017.08.023_bib12","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1093\/eurjhf\/hfq061","article-title":"Bone marrow dysfunction in chronic heart failure patients","volume":"12","author":"Westenbrink","year":"2010","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jchf.2017.08.023_bib13","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.jacc.2004.03.052","article-title":"Prognostic value of plasma erythropoietin on mortality in patients with chronic heart failure","volume":"44","author":"van der Meer","year":"2004","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2017.08.023_bib14","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1002\/ejhf.484","article-title":"High serum erythropoietin levels are related to heart failure development in subjects from the general population with albuminuria: data from PREVEND","volume":"18","author":"Grote Beverborg","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jchf.2017.08.023_bib15","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1161\/CIRCULATIONAHA.105.549121","article-title":"Levels of hematopoiesis inhibitor N-acetyl-seryl-aspartyl-lysyl-proline partially explain the occurrence of anemia in heart failure","volume":"112","author":"van der Meer","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.jchf.2017.08.023_bib16","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.jacc.2004.10.038","article-title":"Angiotensin-converting enzyme inhibitor as a risk factor for the development of anemia, and the impact of incident anemia on mortality in patients with left ventricular dysfunction","volume":"45","author":"Ishani","year":"2005","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2017.08.023_bib17","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1093\/eurheartj\/ehl012","article-title":"The impact of new onset anaemia on morbidity and mortality in chronic heart failure: results from COMET","volume":"27","author":"Komajda","year":"2006","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jchf.2017.08.023_bib18","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1001\/jama.279.3.217","article-title":"Human cardiovascular and metabolic response to acute, severe isovolemic anemia","volume":"279","author":"Weiskopf","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.jchf.2017.08.023_bib19","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.ijcard.2015.11.178","article-title":"The impact of iron deficiency and anaemia on exercise capacity and outcomes in patients with chronic heart failure. Results from the studies investigating co-morbidities aggravating heart failure","volume":"205","author":"Ebner","year":"2016","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jchf.2017.08.023_bib20","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1002\/ejhf.84","article-title":"The\u00a0additive burden of iron deficiency in the cardiorenal-anaemia axis: scope of a problem and its consequences","volume":"16","author":"Klip","year":"2014","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jchf.2017.08.023_bib21","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.ahj.2009.08.001","article-title":"Blood transfusion for acute decompensated heart failure\u2014friend or foe?","volume":"158","author":"Garty","year":"2009","journal-title":"Am Heart J"},{"key":"10.1016\/j.jchf.2017.08.023_bib22","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.amjcard.2010.08.046","article-title":"Characteristics and outcomes among heart failure patients with anemia and renal insufficiency with and without blood transfusions (public discharge data from California 2000-2006)","volume":"107","author":"Kao","year":"2011","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jchf.2017.08.023_bib23","doi-asserted-by":"crossref","first-page":"770","DOI":"10.7326\/0003-4819-159-11-201312030-00009","article-title":"Treatment of anemia in patients with heart disease: a clinical practice guideline from the American College of Physicians","volume":"159","author":"Qaseem","year":"2013","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jchf.2017.08.023_bib24","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1056\/NEJMoa1214865","article-title":"Treatment of anemia with darbepoetin alfa in systolic heart failure","volume":"368","author":"Swedberg","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jchf.2017.08.023_bib25","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1002\/ejhf.412","article-title":"Increased risk of stroke with darbepoetin alfa in anaemic heart failure patients with diabetes and chronic kidney disease","volume":"17","author":"Bello","year":"2015","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jchf.2017.08.023_bib26","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1001\/jama.299.8.914","article-title":"Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia","volume":"299","author":"Bennett","year":"2008","journal-title":"JAMA"},{"key":"10.1016\/j.jchf.2017.08.023_bib27","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1056\/NEJMoa065485","article-title":"Correction of anemia with epoetin alfa in chronic kidney disease","volume":"355","author":"Singh","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jchf.2017.08.023_bib28","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1136\/heartjnl-2012-301954","article-title":"Inflammation and anaemia in a broad spectrum of patients with heart failure","volume":"98","author":"Kleijn","year":"2012","journal-title":"Heart"},{"key":"10.1016\/j.jchf.2017.08.023_bib29","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.cardfail.2013.08.508","article-title":"Differences in blood volume components between hyporesponders and responders to erythropoietin alfa: the Heart Failure With Preserved Ejection Fraction (HFPEF) anemia trial","volume":"19","author":"Borovka","year":"2013","journal-title":"J\u00a0Card Fail"},{"key":"10.1016\/j.jchf.2017.08.023_bib30","first-page":"269","article-title":"Abstract 1293: hyporesponsiveness to darbepoetin alfa in patients with heart failure and anemia in the RED-HF study: clinical and prognostic associations","volume":"17","author":"van Veldhuisen","year":"2015","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jchf.2017.08.023_bib31","doi-asserted-by":"crossref","first-page":"e000345","DOI":"10.1161\/CIRCHEARTFAILURE.115.000345","article-title":"Oral iron therapy for heart failure with reduced ejection fraction: design and rationale for oral iron repletion effects on oxygen uptake in heart failure","volume":"9","author":"Lewis","year":"2016","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jchf.2017.08.023_bib32","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1016\/j.jacc.2007.07.029","article-title":"Intravenous iron reduces NT-pro-brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency","volume":"50","author":"Toblli","year":"2007","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2017.08.023_bib33","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jacc.2007.09.036","article-title":"Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency FERRIC-HF: a randomized, controlled, observer-blinded trial","volume":"51","author":"Okonko","year":"2008","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2017.08.023_bib34","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1056\/NEJMoa0908355","article-title":"Ferric carboxymaltose in patients with heart failure and iron deficiency","volume":"361","author":"Anker","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jchf.2017.08.023_bib35","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1093\/eurheartj\/ehu385","article-title":"Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency","volume":"36","author":"Ponikowski","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jchf.2017.08.023_bib36","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1161\/CIRCULATIONAHA.117.027497","article-title":"Effect of ferric carboxymaltose on exercise capacity in patients with chronic heart failure and iron deficiency","volume":"136","author":"van Veldhuisen","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.jchf.2017.08.023_bib37","first-page":"20","article-title":"Definition of iron deficiency based on the gold standard of bone marrow iron staining and treatment effect of ferric carboxymaltose in heart failure patients","volume":"19","author":"Grote Beverborg","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jchf.2017.08.023_bib38","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/ejhf.823","article-title":"Effects of ferric carboxymaltose on hospitalisations and mortality rates in iron-deficient heart failure patients: an individual patient data meta-analysis","volume":"20","author":"Anker","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jchf.2017.08.023_bib39","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","article-title":"2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"37","author":"Ponikowski","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jchf.2017.08.023_bib40","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1016\/j.jacc.2013.05.019","article-title":"2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines","volume":"62","author":"Yancy","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2017.08.023_bib41","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s13045-017-0427-x","article-title":"A\u00a0first-in-human phase 1 study of a hepcidin monoclonal antibody, LY2787106, in cancer-associated anemia","volume":"10","author":"Vadhan-Raj","year":"2017","journal-title":"J\u00a0Hematol Oncol"},{"key":"10.1016\/j.jchf.2017.08.023_bib42","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1182\/blood-2014-03-559484","article-title":"Effect of the antihepcidin Spiegelmer lexaptepid on inflammation-induced decrease in serum iron in humans","volume":"124","author":"van Eijk","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.jchf.2017.08.023_bib43","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1359\/jbmr.081208","article-title":"Single-dose, randomized, double-blind, placebo-controlled study of ACE-011 (ActRIIA-IgG1) in postmenopausal women","volume":"24","author":"Ruckle","year":"2009","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.jchf.2017.08.023_bib44","first-page":"310A","article-title":"Sotatercept improves anemia, vascular\u00a0calcification, and bone loss in patients with end-stage kidney disease on hemodialysis","volume":"26","author":"Havill","year":"2015","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.jchf.2017.08.023_bib45","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1038\/nm.3524","article-title":"Targeting a new regulator of erythropoiesis to alleviate anemia","volume":"20","author":"Paulson","year":"2014","journal-title":"Nat Med"},{"key":"10.1016\/j.jchf.2017.08.023_bib46","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.exphem.2012.12.002","article-title":"Stromal cell-mediated inhibition of erythropoiesis can be attenuated by Sotatercept (ACE-011), an activin receptor type II ligand trap","volume":"41","author":"Iancu-Rubin","year":"2013","journal-title":"Exp Hematol"},{"key":"10.1016\/j.jchf.2017.08.023_bib47","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/S0959-437X(98)80016-6","article-title":"Hypoxia-inducible factor 1: master regulator of O2 homeostasis","volume":"8","author":"Semenza","year":"1998","journal-title":"Curr Opin Genet Dev"},{"key":"10.1016\/j.jchf.2017.08.023_bib48","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1053\/j.ajkd.2015.06.030","article-title":"New treatment approaches for the anemia of CKD","volume":"67","author":"Bonomini","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.jchf.2017.08.023_bib49","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1093\/ndt\/gfx011","article-title":"Phase 2 studies of oral hypoxia-inducible factor prolyl hydroxylase inhibitor FG-4592 for treatment of anemia in China","volume":"32","author":"Chen","year":"2017","journal-title":"Nephrol Dial Transplant"}],"container-title":["JACC: Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213177917306212?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213177917306212?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,3,3]],"date-time":"2019-03-03T08:57:49Z","timestamp":1551603469000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213177917306212"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3]]},"references-count":49,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["S2213177917306212"],"URL":"https:\/\/doi.org\/10.1016\/j.jchf.2017.08.023","relation":{},"ISSN":["2213-1779"],"issn-type":[{"value":"2213-1779","type":"print"}],"subject":[],"published":{"date-parts":[[2018,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anemia in Heart Failure","name":"articletitle","label":"Article Title"},{"value":"JACC: Heart Failure","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jchf.2017.08.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 by the American College of Cardiology Foundation. Published by Elsevier.","name":"copyright","label":"Copyright"}]}}